Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1065989 | 0.88 | GPR119 (0.79) | GPR119 | |
| SCHEMBL514317 | 0.88 | GPR119 (1.00) | GPR119 | |
| SCHEMBL1066531 | 0.86 | GPR119 (0.68) | GPR119ROCK1 | |
| SCHEMBL8512802 | 0.84 | GPR119 (0.57) | GPR119ROCK1 | |
| SCHEMBL1064995 | 0.84 | GPR119 (0.64) | GPR119ROCK1 | |
| SCHEMBL299959 | 0.83 | GPR119 (0.80) | GPR119 | |
| SCHEMBL2717368 | 0.78 | GPR119 (0.72) | GPR119ROCK1 | |
| SCHEMBL515122 | 0.78 | GPR119 (0.61) | GPR119ROCK1 | |
| SCHEMBL288283 | 0.77 | GPR119 (0.64) | GPR119ROCK1 | |
| SCHEMBL17091631 | 0.77 | GPR119 (0.64) | GPR119ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410089-B2 | Fused heterocyclic ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-04-02 | — | — | US | disclosed |
| EP-2445901-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | Boehringer Ingelheim International GmbH (DE) | 2012-05-02 | — | — | EP | disclosed |
| US-20120028962-A1 | FUSED HETEROCYCLIC RING COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-02 | — | — | US | disclosed |
| EP-2399914-A1 | FUSED HETEROCYCLIC RING COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-12-28 | — | — | EP | disclosed |
| WO-2010149685-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028962-A1 | FUSED HETEROCYCLIC RING COMPOUND | GPR119, GPR4, GPR84 | GPR119 1/4885ROCK1 2566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.